Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well abemaciclib works in treating patients with digestive
system neuroendocrine tumors that have spread to other places in the body, do not respond to
treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
Eli Lilly and Company National Cancer Institute (NCI)